Role of identified proteins in the proteome profiles of CDK4/6 inhibitor-resistant breast cancer cell lines
Molecular Omics · 2023
DOI: 10.1039/d2mo00285j ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Omics, 2023. Verfasst von Binayak Kumar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular Oncology, ICMR-National Institute of Cancer Prevention and Research, I-7, Sector-39, Noida, Uttar Pradesh, 201301, India. sures…. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Indian Council of Medical Research.
Abstract (Originalsprache)
Abemaciclib (Ab) and palbociclib (Pb) are CDK4/6 inhibitors used to cure advanced breast cancer (BC). However, acquired resistance is a major challenge. The molecular mechanisms and signature proteins of therapy resistance for Ab and Pb drugs need to be explored. Here we developed resistant cells for Ab and Pb drugs in MCF-7 cell lines and explored the mechanisms and signature proteins of therapy resistance in BC. Proteome profiling was performed using the label-free proteome-orbitrap-fusion-MS-MS technique. Gene ontology (GO)-terms, KEGG pathways and network analysis were performed for the proteome data. Drug-resistant cells showed increased drug tolerance, enhanced colony formation potential and an increased gap-healing tendency for the respective drug. Up-regulation of survival genes (BCL-2 and MCL-1) and down-regulation of apoptosis inducers were observed. Drug-resistance markers (MDR-1 and ABCG2 (BCRP)) along with ESR-1, CDK4, CDK6, and cyclin-D1 genes were up-regulated in resistant cells. A total of 237 and 239 proteins were found to be differentially expressed in the Ab and Pb-resistant cells, respectively. Down-regulated proteins induce apoptosis signalling and nucleotide metabolisms and restrict EGFR signalling; however, up-regulated proteins induce Erk, wnt-β-catenin, VEGFR-PI3K-AKT, glucose transportation, and hypoxia signalling pathways and regulate hydrogen peroxide signalling pathways. The panel of identified proteins associated with these pathways might have characteristics of molecular signature and new drug targets for overcoming drug resistance in breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Molecular Oncology, ICMR-National Institute of Cancer Prevention and Research, I-7, Sector-39, Noida, Uttar Pradesh, 201301, India. suresh.hedau@gov.in.
- Department of Research, Sir Ganga Ram Hospital, 110060, New Delhi, India.
- Department of Life Sciences, Shiv Nadar University, NH-91, Tahsil-Dadri, Distt-Gautam Budhaa Nagar, Uttar Pradesh, 201314, India. jayadevmsk@snu.edu.in.
ORCID-Profile: Ashutosh Singh, Suresh Hedau
Förderung
- Indian Council of Medical Research
Zitieren
APA
Kumar, B., Prasad, P., Singh, R., Sahu, R. K., Singh, A., Magani, S. J., & Hedau, S. (2023). Role of identified proteins in the proteome profiles of CDK4/6 inhibitor-resistant breast cancer cell lines. Molecular Omics. https://doi.org/10.1039/d2mo00285j
Vancouver
Kumar B, Prasad P, Singh R, Sahu RK, Singh A, Magani SJ, et al. Role of identified proteins in the proteome profiles of CDK4/6 inhibitor-resistant breast cancer cell lines. Molecular Omics. 2023. doi:10.1039/d2mo00285j
BibTeX
@article{Kumar2023,
author = {Kumar, Binayak and Prasad, Peeyush and Singh, Ragini and Sahu, Ram Krishna and Singh, Ashutosh and Magani, Srikrishna Jayadev and Hedau, Suresh},
title = {Role of identified proteins in the proteome profiles of CDK4/6 inhibitor-resistant breast cancer cell lines},
journal = {Molecular Omics},
year = {2023},
doi = {10.1039/d2mo00285j}
}
EUVIMED